Efficacy, safety, and current applications of brimonidine.
BACKGROUND
The use of brimonidine to lower intraocular pressure has been the subject of considerable investigation. Variations of the initially approved drug including agents of a lower concentration (Alphagan P 0.15 and 0.1%, Allergan, Inc., Irvine, CA, USA) and a fixed-combination mating brimonidine with timolol (Combigan, Allergan) evolved the marketing and application of this therapy.


OBJECTIVE
We review available evidence regarding the efficacy and side effect profile of brimonidine as well as its role in glaucoma management.


CONCLUSIONS
Brimonidine is an important component of topical glaucoma treatment that is most limited by local ocular intolerance.
Fudemberg
Scott J
SJ
Wills Eye Institute, Instructor, Jefferson Medical College Anna and William Goldberg Glaucoma Service and Research Center, 840 Walnut St. Ste 1130, Philadelphia, PA 19107, USA. sfudemberg@willseye.org
Batiste
Corey
C
Katz
L Jay
LJ
D000818:Animals; D000959:Antihypertensive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000068438:Brimonidine Tartrate; D004338:Drug Combinations; D005901:Glaucoma / Q000188:drug therapy*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D009798:Ocular Hypertension / Q000188:drug therapy; D009883:Ophthalmic Solutions; D011810:Quinoxalines / Q000008:administration & dosage* / Q000009:adverse effects; D013999:Timolol / Q000008:administration & dosage; D016896:Treatment Outcome
D000959:Antihypertensive Agents; D004338:Drug Combinations; D009883:Ophthalmic Solutions; D011810:Quinoxalines; D000068438:Brimonidine Tartrate; D013999:Timolol